New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires

Stock News

3小时前

The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, SDIC Securities International acted as its sole sponsor.

According to the previous prospectus, Kangnuo Biotech is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.

The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1144335647"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144335647\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1144335647?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-27 07:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144335647","market":"other","top_or_hot":-1,"title":"New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires","media":"Stock News","content":"<p>The prospectus submitted by <b>Kangnuo Biotech Pharmaceutical Co., Ltd</b> (referred to as <b>Kangnuo Biotech</b>) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, <b>SDIC Securities International</b> acted as its sole sponsor.<br><br>According to the previous prospectus, <b>Kangnuo Biotech</b> is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.<br><br>The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>New Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNew Stock Update: Kangnuo Biotech's Hong Kong IPO Prospectus Expires\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-27 07:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The prospectus submitted by <b>Kangnuo Biotech Pharmaceutical Co., Ltd</b> (referred to as <b>Kangnuo Biotech</b>) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, <b>SDIC Securities International</b> acted as its sole sponsor.<br><br>According to the previous prospectus, <b>Kangnuo Biotech</b> is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.<br><br>The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REDS","symbol_name":"RPM Republican Senate ETF","start_time":0,"source_url":"","article_id":"1144335647","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144335647","pubTimestamp":1785107898,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REDS":"RPM Republican Senate ETF","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK4127":"投资银行业与经纪业","IPOS":"Renaissance International IPO ETF","KCE":"SPDR KBW Capital Markets ETF","FRHC":"Euronext CAC Health Care","KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股"},"translate_title":"新股更新：康诺生物香港IPO招股说明书到期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REDS":1,"VXUS":1,"KCAI":1,"IPOS":1,"KCE":1,"FRHC":1},"content_text":"The prospectus submitted by Kangnuo Biotech Pharmaceutical Co., Ltd (referred to as Kangnuo Biotech) for its Hong Kong IPO on January 25, 2026, has expired after six months, on July 25, 2026. At the time of filing, SDIC Securities International acted as its sole sponsor.According to the previous prospectus, Kangnuo Biotech is a biopharmaceutical enterprise focused on the research and development, drug production, and commercialization of mitochondrial medicine and health products.The company specializes in studying diseases caused by mitochondrial dysfunction, dedicating its efforts to applying NAD+ in scientific research areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}